Clinical Trials on Muscle-invasive Bladder Cancer

Total 1796 results

Aura Biosciences

Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
AstraZeneca
Hospital Israelita Albert Einstein

Recruiting

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER

Urothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder Cancer

Brazil
Nucleix Ltd.

Completed

Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

Non Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
University of Virginia
American Cancer Society, Inc.; Integrated Translational Health Research Institute...

Recruiting

Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) (PRIMER)

Bladder Cancer | Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
University of Roma La Sapienza

Not yet recruiting

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) (CUT-less)

Non-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Huazhong University of Science and Technology

Recruiting

The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients

Bladder Cancer | Non-Muscle-Invasive Bladder Cancer

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC

Non-Muscle-Invasive Bladder Cancer (NMIBC)

China
RenJi Hospital
BeiGene; RemeGen Co., Ltd.

Recruiting

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

HER2 | Non-Muscle Invasive Bladder Cancer

China
White River Junction Veterans Affairs Medical Center
Medical University of South Carolina; National Cancer Institute (NCI); University...

Recruiting

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance (ReplaceCysto)

Non-muscle-invasive Bladder Cancer

United States
Al-Azhar University

Recruiting

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

Non-muscle-invasive Bladder Cancer

Egypt
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)

Non-muscle-invasive Bladder Cancer

United States
VA Office of Research and Development
University of California, Davis

Recruiting

A Phase I Intravesical PPM Therapy for NMIBC

Non-muscle-invasive Bladder Cancer

United States
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR)

Recruiting

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (BicaBCa)

Non-Muscle Invasive Bladder Cancer

Canada
Clinical Hospital Centre Zagreb

Active, not recruiting

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

Croatia
Archivel Farma S.L.
Fundació Institut Germans Trias i Pujol

Completed

Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI® (RUTIVAC-1)

High-Risk Non-Muscle-Invasive Bladder Cancer

Spain
RemeGen Co., Ltd.

Not yet recruiting

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

High-risk Non-muscle Invasive Bladder Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection

Non Muscle Invasive Bladder Cancer

China
AstraZeneca
Parexel

Recruiting

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO)

Non-Muscle- Invasive Bladder Cancer

United States
University of Texas Southwestern Medical Center

Recruiting

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

Non-muscle-invasive Bladder Cancer

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Non-Muscle Invasive Bladder Cancer (NMIBC)

United States
Istari Oncology, Inc.

Active, not recruiting

LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Solid Tumor | Bladder Cancer | Non-muscle-invasive Bladder Cancer

United States
AstraZeneca

Active, not recruiting

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC)

Non-muscle-invasive Bladder Cancer

France, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
Ractigen Therapeutics.

Recruiting

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Australia
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

Non-Muscle Invasive Bladder Cancer

United States, Israel
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

High-risk Non-muscle Invasive Bladder Cancer

China
Johns Hopkins University

Recruiting

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

Non-Muscle Invasive Bladder Cancer

United States
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

China
ImmunityBio, Inc.

Active, not recruiting

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Non Muscle Invasive Bladder Cancer

United States
CG Oncology, Inc.

Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder Cancer

United States
enGene, Inc.

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Superficial Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

United States
SURGE Therapeutics

Recruiting

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Non-muscle-invasive Bladder Cancer

United States
Pharmalink

Active, not recruiting

External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group (EVALUATION)

Non-muscle-invasive Bladder Cancer

Spain
Fundacion Oncosur
Apices Soluciones S.L.

Active, not recruiting

Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) (BladderGATE)

Invasive Bladder Cancer

Spain
Prokarium Ltd

Recruiting

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer (PARADIGM-1)

NMIBC | Non Muscle Invasive Bladder Cancer | High Risk NMIBC

United States
Fidia Farmaceutici s.p.a.

Terminated

Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.

Non-muscle Invasive Bladder Cancer (NMIBC)

Italy
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Co... and more
IRCCS San Raffaele

Recruiting

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Bladder Cancer | Bladder Disease | Bladder Cancer Recurrent | Bladder Urothelial Carcinoma | Non Muscle Invasive Bladder Cancer | Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Non-Muscle Invasive Bladder Neoplasms | Bladder Cancer Stage I, With Cancer in Situ | Bladder Urothelial... and other conditions

Italy
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

Non-Muscle-Invasive Bladder Cancer
Chengdu CoenBiotech Co., Ltd
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Non-Muscle Invasive Bladder Cancer

China
University of British Columbia

Withdrawn

Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer (Rideau)

Bladder Cancer | High-Risk Cancer | Durvalumab | Non-muscle Invasive | Tremelimumab

Canada
Ain Shams University

Completed

Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer

Urinary Bladder Cancer | BCG | Urinary Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Trans Urethral Resection of a Bladder Tumor

Egypt
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Vitadx
FONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTE

Recruiting

Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test (DMIA)

Non-muscle Invasive Bladder Cancer (NMIBC)

France, Belgium, Spain
National Cancer Institute (NCI)

Not yet recruiting

Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
University of Trieste

Completed

Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer (START)

Bladder Cancer | Non Muscle Invasive Bladder Cancer

Italy
Academisch Medisch Centrum - Universiteit van Amsterdam...
Radboud University Medical Center

Recruiting

Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer (TROJAN)

Bladder Cancer | Superficial Bladder Cancer

Netherlands
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed Carcinoma

United States, Guam, Puerto Rico
Ferring Pharmaceuticals
FKD Therapies Oy; Society of Urologic Oncology Clinical Trials Consortium

Completed

ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Superficial Bladder Cancer

United States
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)

Muscle Invasive Bladder Cancer

United States, China
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Withdrawn

Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study (PECULIAR)

Muscle-invasive Bladder Cancer

Italy

Clinical Trials on Muscle-invasive Bladder Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations